Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT ID: NCT02477696
Last Updated: 2025-11-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
533 participants
INTERVENTIONAL
2015-07-28
2028-01-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
NCT04008706
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia
NCT04178798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acalabrutinib
Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.
Acalabrutinib
Participants will receive oral acalabrutinib as stated in arm description.
Ibrutinib
Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.
Ibrutinib
Participants will receive oral ibrutinib as stated in arm description.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acalabrutinib
Participants will receive oral acalabrutinib as stated in arm description.
Ibrutinib
Participants will receive oral ibrutinib as stated in arm description.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status of 0 to 2.
* Diagnosis of CLL.
* Must have ≥ 1 of the following high-risk prognostic factors:
* Presence of 17p del by central laboratory.
* Presence of 11q del by central laboratory.
* Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment
* Must have received ≥ 1 prior therapies for CLL.
* Meet the following laboratory parameters:
* Absolute neutrophil count (ANC) ≥ 750 cells/μL or ≥ 500 cells/μL in participants with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
* Platelet count ≥ 30,000 cells/μL without transfusion support 7 days before assessment. Participants with transfusion-dependent thrombocytopenia are excluded.
* Serum aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤ 3.0 x upper limit of normal (ULN).
* Total bilirubin ≤ 1.5 x ULN.
* Estimated creatinine clearance ≥ 30 mL/min.
Exclusion Criteria
* Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
* Prior exposure to ibrutinib or to a B-cell receptor (BCR) inhibitor or a B-cell lymphoma-2 (BCL-2) inhibitor.
* Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
* Prior radio- or toxin-conjugated antibody therapy.
* Prior allogeneic stem cell or autologous transplant.
* Major surgery within 4 weeks before first dose of study drug.
* Prior malignancy, except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, in situ cervical carcinoma or other malignancy treated with no evidence of active disease \> 3 years before Screening and at low risk for recurrence.
* Significant cardiovascular disease within 6 months of screening.
* Known history of infection with human immunodeficiency virus (HIV).
* History of stroke or intracranial hemorrhage within 6 months before randomization.
* History of bleeding diathesis.
* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.
* Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor/inducer.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acerta Pharma BV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Acerta Clinical Trials
Role: STUDY_DIRECTOR
1-888-292-9613
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Phoenix, Arizona, United States
Research Site
Anaheim, California, United States
Research Site
Berkeley, California, United States
Research Site
Duarte, California, United States
Research Site
La Jolla, California, United States
Research Site
Los Angeles, California, United States
Research Site
Palo Alto, California, United States
Research Site
Santa Rosa, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Athens, Georgia, United States
Research Site
Harvey, Illinois, United States
Research Site
Peoria, Illinois, United States
Research Site
Wichita, Kansas, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Rochester, Minnesota, United States
Research Site
Billings, Montana, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Lake Success, New York, United States
Research Site
New Hyde Park, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Columbus, Ohio, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Houston, Texas, United States
Research Site
Round Rock, Texas, United States
Research Site
Charlottesville, Virginia, United States
Research Site
Tacoma, Washington, United States
Research Site
Northwest WA, Wisconsin, United States
Research Site
Darlinghurst, , Australia
Research Site
Frankston, , Australia
Research Site
Melbourne, , Australia
Research Site
St Leonards, , Australia
Research Site
Waratah NSW, , Australia
Research Site
Wollongong, , Australia
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Yvoir, , Belgium
Research Site
Aalborg, , Denmark
Research Site
Indgang 27B, , Denmark
Research Site
Bobigny, , France
Research Site
Créteil, , France
Research Site
Pierre-Bénite, , France
Research Site
Rennes, , France
Research Site
Rouen, , France
Research Site
Toulouse, , France
Research Site
München, , Germany
Research Site
Ulm, , Germany
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Haifa, , Israel
Research Site
Haifa, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Nahariya, , Israel
Research Site
Petah Tikvah, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Tiberias, , Israel
Research Site
Bologna, , Italy
Research Site
Cagliari, , Italy
Research Site
Cona, , Italy
Research Site
Florence, , Italy
Research Site
Meldola, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Modena, , Italy
Research Site
Ravenna, , Italy
Research Site
Rome, , Italy
Research Site
Almere Stad, , Netherlands
Research Site
Amsterdam, , Netherlands
Research Site
Blaricum, , Netherlands
Research Site
Breda, , Netherlands
Research Site
Delft, , Netherlands
Research Site
Dordrecht, , Netherlands
Research Site
Geleen, , Netherlands
Research Site
Groningen, , Netherlands
Research Site
Haarlem, , Netherlands
Research Site
Leiden, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Zutphens, , Netherlands
Research Site
Addington, , New Zealand
Research Site
Auckland, , New Zealand
Research Site
Tauranga, , New Zealand
Research Site
Bydgoszcz, , Poland
Research Site
Gdansk, , Poland
Research Site
Gdynia, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Olsztyn, , Poland
Research Site
Opole, , Poland
Research Site
Słupsk, , Poland
Research Site
Wroclaw, , Poland
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Murcia, , Spain
Research Site
Santander, , Spain
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Instabul, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kayseri, , Turkey (Türkiye)
Research Site
Birmingham, , United Kingdom
Research Site
Bournemouth, , United Kingdom
Research Site
Cambridge, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Greater London, , United Kingdom
Research Site
Hull, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Southampton, , United Kingdom
Research Site
Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Byrd JC, Hakre S, Ghia P. How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studies. Future Oncol. 2025 Nov;21(26):3343-3357. doi: 10.1080/14796694.2025.2494976. Epub 2025 Jun 8.
Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, Ahmed HH, Fatima K, Malhan H, Qadri I, Almehdar H. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies. Adv Hematol. 2024 Nov 12;2024:5948170. doi: 10.1155/2024/5948170. eCollection 2024.
Woyach JA, Jones D, Jurczak W, Robak T, Illes A, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024 Sep 5;144(10):1061-1068. doi: 10.1182/blood.2023023659.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818.
Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illes A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509347-27-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2014-005530-64
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ACE-CL-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.